This may be of additive value to available RA treatment with conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs), such as methotrexate and hydroxychloroquine, and/or biological DMARDs like adalimumab (anti-TNFα) or tocilizumab (anti-IL-6R), which still face inadequate responses in part of the RA patients [17]. This evidence concerns the gene IL6R and rheumatoid arthritis.